{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:07:40Z","timestamp":1793815660726,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA176067-01A1"],"award-info":[{"award-number":["U01 CA176067-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","award":["CA-16359"],"award-info":[{"award-number":["CA-16359"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10585-024-10297-z","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T18:01:36Z","timestamp":1719079296000},"page":"765-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody\u2013drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2"],"prefix":"10.1007","volume":"41","author":[{"given":"Levent","family":"Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego D.","family":"Manavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Skyler Z.","family":"Verzosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Harold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang-Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zipponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Altwerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaagn","family":"Andikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"10297_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A, Cancer statistics, CA, Cancer JC (2024) 2024 Jan-Feb;74(1):12\u201349. doi: 10.3322\/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. PMID: 38230766","DOI":"10.3322\/caac.21820"},{"key":"10297_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2017) SEER Cancer Statistics Review, 1975\u20132014, National Cancer Institute, Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2014\/"},{"key":"10297_CR3","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Gynecologic Oncology Group, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200. https:\/\/doi.org\/10.1200\/JCO.2003.02.153","journal-title":"J Clin Oncol"},{"key":"10297_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck H-J, Meier W, Adams H-P, M\u00f6bus V, Costa S, Bauknecht T, Richter B, Warm M, Schr\u00f6der W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Ovarian Cancer Study Group, a randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320\u20131329. https:\/\/doi.org\/10.1093\/jnci\/djg036","journal-title":"J Natl Cancer Inst"},{"key":"10297_CR5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","volume":"329","author":"SA Cannistra","year":"1993","unstructured":"Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329:1550\u20131559. https:\/\/doi.org\/10.1056\/NEJM199311183292108","journal-title":"N Engl J Med"},{"key":"10297_CR6","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1073\/pnas.0806514106","volume":"106","author":"HB Salvesen","year":"2009","unstructured":"Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, B\u00f8 TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 106:4834\u20134839. https:\/\/doi.org\/10.1073\/pnas.0806514106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10297_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/1471-2407-11-294","volume":"11","author":"A Noske","year":"2011","unstructured":"Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl A-C, Sehouli J, Braicu EI, Budczies J, Dietel M, Denkert C (2011) An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 11:294. https:\/\/doi.org\/10.1186\/1471-2407-11-294","journal-title":"BMC Cancer"},{"key":"10297_CR8","doi-asserted-by":"publisher","first-page":"e1138","DOI":"10.1371\/journal.pone.0001138","volume":"2","author":"M Tuefferd","year":"2007","unstructured":"Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Bro\u00ebt P, Guastalla J-P, Allouache D, Combe M, Weber B, Pujade-Lauraine E (2007) Camilleri-Bro\u00ebt, HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2:e1138. https:\/\/doi.org\/10.1371\/journal.pone.0001138","journal-title":"PLoS ONE"},{"key":"10297_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jmoldx.2015.04.003","volume":"17","author":"W Wen","year":"2015","unstructured":"Wen W, Chen WS, Xiao N, Bender R, Ghazalpour A, Tan Z, Swensen J, Millis SZ, Basu G, Gatalica Z, Press MF (2015) Mutations in the kinase domain of the HER2\/ERBB2 gene identified in a wide Variety of Human cancers. J Mol Diagn 17:487\u2013495. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.04.003","journal-title":"J Mol Diagn"},{"key":"10297_CR10","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T (2016) DS-8201a, A Novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a Promising Antitumor Efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097\u20135108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822","journal-title":"Clin Cancer Res"},{"key":"10297_CR11","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","volume":"21","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos M-A, Zagouri F (2021) Trastuzumab Deruxtecan (DS-8201a): the latest research and advances in breast Cancer. Clin Breast Cancer 21:e212\u2013e219. https:\/\/doi.org\/10.1016\/j.clbc.2020.08.006","journal-title":"Clin Breast Cancer"},{"key":"10297_CR12","doi-asserted-by":"publisher","first-page":"111682","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J, Yu D (2019) Novel HER2-Targeting antibody-drug conjugates of Trastuzumab Beyond T-DM1 in breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem 183:111682. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111682","journal-title":"Eur J Med Chem"},{"key":"10297_CR13","doi-asserted-by":"publisher","first-page":"847835","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X (2022) Antibody-drug conjugates targeting the Human Epidermal Growth Factor Receptor Family in cancers. Front Mol Biosci 9:847835. https:\/\/doi.org\/10.3389\/fmolb.2022.847835","journal-title":"Front Mol Biosci"},{"key":"10297_CR14","unstructured":"O. of the Commissioner, FDA Approves First Targeted Therapy for HER2-Low Breast Cancer, FDA (2022) https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-her2-low-breast-cancer (accessed February 3, 2023)"},{"key":"10297_CR15","unstructured":"Research (2022) FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer, FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung (accessed February 3, 2023)"},{"key":"10297_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1073\/pnas.1814027116","volume":"116","author":"C Li","year":"2019","unstructured":"Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi D-A, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD (2019) Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proc Natl Acad Sci U S A 116:619\u2013624. https:\/\/doi.org\/10.1073\/pnas.1814027116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10297_CR17","doi-asserted-by":"publisher","first-page":"175883592098651","DOI":"10.1177\/1758835920986518","volume":"13","author":"D Kotani","year":"2021","unstructured":"Kotani D, Shitara K (2021) Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol 13:1758835920986518. https:\/\/doi.org\/10.1177\/1758835920986518","journal-title":"Ther Adv Med Oncol"},{"key":"10297_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","volume":"145","author":"N Buza","year":"2021","unstructured":"Buza N (2021) HER2 testing in Endometrial Serous Carcinoma: time for standardized Pathology Practice to meet the clinical demand. Arch Pathol Lab Med 145:687\u2013691. https:\/\/doi.org\/10.5858\/arpa.2020-0207-RA","journal-title":"Arch Pathol Lab Med"},{"key":"10297_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","volume":"199","author":"E Cocco","year":"2019","unstructured":"Cocco E, Lopez S, Santin AD, Scaltriti M (2019) Prevalence and role of HER2 mutations in cancer. Pharmacol Ther 199:188\u2013196. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.03.010","journal-title":"Pharmacol Ther"},{"key":"10297_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/14728222.12.3.353","volume":"12","author":"J Reibenwein","year":"2008","unstructured":"Reibenwein J, Krainer M (2008) Targeting signaling pathways in ovarian cancer. Expert Opin Ther Targets 12:353\u2013365. https:\/\/doi.org\/10.1517\/14728222.12.3.353","journal-title":"Expert Opin Ther Targets"},{"key":"10297_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3978\/j.issn.2218-6751.2013.02.02","volume":"2","author":"AC Garrido-Castro","year":"2013","unstructured":"Garrido-Castro AC, Felip E (2013) HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl Lung Cancer Res 2:122\u2013127. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2013.02.02","journal-title":"Transl Lung Cancer Res"},{"key":"10297_CR22","doi-asserted-by":"publisher","first-page":"e98528","DOI":"10.1371\/journal.pone.0098528","volume":"9","author":"AN Seo","year":"2014","unstructured":"Seo AN, Kwak Y, Kim D-W, Kang S-B, Choe G, Kim WH, Lee HS (2014) HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS ONE 9:e98528. https:\/\/doi.org\/10.1371\/journal.pone.0098528","journal-title":"PLoS ONE"},{"key":"10297_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bjc.2011.62","volume":"104","author":"Q Sheng","year":"2011","unstructured":"Sheng Q, Liu J (2011) The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 104:1241\u20131245. https:\/\/doi.org\/10.1038\/bjc.2011.62","journal-title":"Br J Cancer"},{"key":"10297_CR24","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748. https:\/\/doi.org\/10.1155\/2014\/852748","journal-title":"Mol Biol Int"},{"key":"10297_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","volume":"32","author":"A Serrano-Olvera","year":"2006","unstructured":"Serrano-Olvera A, Due\u00f1as-Gonz\u00e1lez A, Gallardo-Rinc\u00f3n D, Candelaria M (2006) De La Garza-Salazar, Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32:180\u2013190. https:\/\/doi.org\/10.1016\/j.ctrv.2006.01.001","journal-title":"Cancer Treat Rev"},{"key":"10297_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283\u2013290. https:\/\/doi.org\/10.1200\/JCO.2003.10.104","journal-title":"J Clin Oncol"},{"key":"10297_CR27","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1349-7006.2002.tb01231.x","volume":"93","author":"M Fujimura","year":"2002","unstructured":"Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S (2002) HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 93:1250\u20131257. https:\/\/doi.org\/10.1111\/j.1349-7006.2002.tb01231.x","journal-title":"Jpn J Cancer Res"},{"key":"10297_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.13704","volume":"73","author":"T Koopman","year":"2018","unstructured":"Koopman T, van der Vegt B, Dijkstra M, Bart J, Duiker E, Wisman GBA, de Bock GH, Hollema H (2018) HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology 73:852\u2013863. https:\/\/doi.org\/10.1111\/his.13704","journal-title":"Histopathology"},{"key":"10297_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM (2014) Antibody-drug conjugates: current status and future directions. Drug Discov Today 19:869\u2013881. https:\/\/doi.org\/10.1016\/j.drudis.2013.11.004","journal-title":"Drug Discov Today"},{"key":"10297_CR30","unstructured":"Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P (1990) Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50"},{"key":"10297_CR31","doi-asserted-by":"publisher","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh D-Y, Banerjee SN, Gonzalez Martin A, Jung KH, Lugowska IA, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Anoka C, Ma Y, Puvvada SD, Lee J-Y (2023) Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol 41. https:\/\/doi.org\/10.1200\/jco.2023.41.17_suppl.lba3000","DOI":"10.1200\/jco.2023.41.17_suppl.lba3000"},{"key":"10297_CR32","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan P, Osgood CL, Singh H, Chiu H-J, Ricks TK, Chiu Yuen Chow E, Qiu J, Song P, Yu J, Namuswe F, Guiterrez-Lugo M, Hou S, Pierce WF, Goldberg KB, Tang S, Amiri-Kordestani L, Theoret MR, Pazdur R, Beaver JA (2021) FDA approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the treatment of unresectable or metastatic HER2-Positive breast Cancer. Clin Cancer Res 27:4478\u20134485. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4557","journal-title":"Clin Cancer Res"},{"key":"10297_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11864-021-00884-7","volume":"22","author":"BC Grieb","year":"2021","unstructured":"Grieb BC, Agarwal R (2021) HER2-Directed Therapy in Advanced gastric and gastroesophageal adenocarcinoma: triumphs and troubles. Curr Treat Options Oncol 22:88. https:\/\/doi.org\/10.1007\/s11864-021-00884-7","journal-title":"Curr Treat Options Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10297-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10297-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10297-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:45:24Z","timestamp":1729745124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10297-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10297"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10297-z","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.D.S. reports grants from PUMA, grants from IMMUNOMEDICS, grants from GILEAD, grants from SYNTHON, grants and personal fees from MERCK, grants from BOEHINGER-INGELHEIM, grants from GENENTECH, grants and personal fees from TESARO and grants and personal fees from EISAI and R-Pharm USA. The other authors declare no conflict of interest. G.S.H reports consulting fees from GlaxoSmithKline and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}